WO1996033984A1 - N-sulfoxy anhydrides, a process for the preparation thereof and its use for the preparation of bioactive substances having ace inhibitory action - Google Patents
N-sulfoxy anhydrides, a process for the preparation thereof and its use for the preparation of bioactive substances having ace inhibitory action Download PDFInfo
- Publication number
- WO1996033984A1 WO1996033984A1 PCT/SI1996/000009 SI9600009W WO9633984A1 WO 1996033984 A1 WO1996033984 A1 WO 1996033984A1 SI 9600009 W SI9600009 W SI 9600009W WO 9633984 A1 WO9633984 A1 WO 9633984A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- preparation
- compound
- sulfoxy
- anhydrides
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 19
- 150000008064 anhydrides Chemical class 0.000 title claims abstract description 9
- 238000002360 preparation method Methods 0.000 title abstract description 23
- 239000000126 substance Substances 0.000 title abstract description 6
- 230000000975 bioactive effect Effects 0.000 title abstract description 4
- 230000002401 inhibitory effect Effects 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims abstract description 17
- 229960002051 trandolapril Drugs 0.000 claims abstract description 17
- 239000005541 ACE inhibitor Substances 0.000 claims abstract description 13
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims abstract description 13
- 108010061435 Enalapril Proteins 0.000 claims abstract description 10
- 229960000873 enalapril Drugs 0.000 claims abstract description 8
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims abstract description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 5
- 125000006239 protecting group Chemical group 0.000 claims abstract description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 18
- 229940024606 amino acid Drugs 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 14
- 229930182821 L-proline Natural products 0.000 claims description 14
- 229960002429 proline Drugs 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 6
- -1 alkyl imidazole Chemical compound 0.000 claims description 6
- 150000002391 heterocyclic compounds Chemical class 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 150000003536 tetrazoles Chemical class 0.000 claims description 3
- 238000001226 reprecipitation Methods 0.000 claims description 2
- 238000001953 recrystallisation Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 14
- 238000003786 synthesis reaction Methods 0.000 abstract description 14
- 239000000543 intermediate Substances 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 48
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- JDIIGWSSTNUWGK-UHFFFAOYSA-N 1h-imidazol-3-ium;chloride Chemical compound [Cl-].[NH2+]1C=CN=C1 JDIIGWSSTNUWGK-UHFFFAOYSA-N 0.000 description 9
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 7
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- CEIWXEQZZZHLDM-AAEUAGOBSA-N (2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoic acid Chemical compound CCOC(=O)[C@@H](N[C@@H](C)C(O)=O)CCC1=CC=CC=C1 CEIWXEQZZZHLDM-AAEUAGOBSA-N 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000012452 mother liquor Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- CQYBNXGHMBNGCG-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-indol-1-ium-2-carboxylate Chemical compound C1CCCC2NC(C(=O)O)CC21 CQYBNXGHMBNGCG-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QNSWMJYOGMUVGO-REWXTUPXSA-N (2s,3ar,7as)-1-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid;hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@@H]2C[C@H]1C(O)=O)CC1=CC=CC=C1 QNSWMJYOGMUVGO-REWXTUPXSA-N 0.000 description 2
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 2
- SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- 229910006124 SOCl2 Inorganic materials 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 2
- 229960000309 enalapril maleate Drugs 0.000 description 2
- GFZFELCFSBCPDB-AAEUAGOBSA-N ethyl (2s)-2-[(4s)-4-methyl-2,5-dioxo-1,3-oxazolidin-3-yl]-4-phenylbutanoate Chemical compound C([C@@H](C(=O)OCC)N1C(OC(=O)[C@@H]1C)=O)CC1=CC=CC=C1 GFZFELCFSBCPDB-AAEUAGOBSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- PKLCVRCOVYAZKN-UHFFFAOYSA-N imidazole-1-sulfinyl chloride Chemical compound ClS(=O)N1C=CN=C1 PKLCVRCOVYAZKN-UHFFFAOYSA-N 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N methylimidazole Natural products CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 2
- INIZYHLLMGAMPL-UHFFFAOYSA-N 1h-imidazole-2-sulfinyl chloride Chemical compound ClS(=O)C1=NC=CN1 INIZYHLLMGAMPL-UHFFFAOYSA-N 0.000 description 1
- PDELQDSYLBLPQO-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-indole Chemical group C1CCCC2NCCC21 PDELQDSYLBLPQO-UHFFFAOYSA-N 0.000 description 1
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 1
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- CSFFRLZLOYZDHJ-UHFFFAOYSA-N benzimidazole-1-sulfinyl chloride Chemical compound C1=CC=C2N(S(=O)Cl)C=NC2=C1 CSFFRLZLOYZDHJ-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
- C07D291/02—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms not condensed with other rings
- C07D291/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
- C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- N-sulfoxy anhydrides a process for the preparation thereof and its use for the preparation of bioactive substances having ACE inhibitory action
- the second type uses e.g. N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-N- carboxy-anhydride (NCA; see the formula (II) below) as reactant.
- NCA N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-N- carboxy-anhydride
- EP 0215335 A2 the reaction of N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanine of the formula (I)
- R 1 represents PhCFH 2 -CH 2 - or CH 3 CH 2 CH 2 - and R 2 represents methyl or R 3 -NH-(CH 2 ) 3 -CH 2 ,-, R 3 being an amino protecting group, preferably CF 3 CO-.
- the second object of the invention is a process for the preparation of novel N-sulfoxy anhydrides of the formula (III), characterized in that a compound of the formula (IV)
- R 1 in R 2 have the above meanings
- R 4 represents the rest of imidazole, of alkyl imidazole, of benzimidazole, of tetrazole and of similar other heterocyclic compounds.
- the reaction between the compound of the formula (IV) and the compound ot the general formula (V) is carried out in dry organic solvents (humidity ⁇ 0.04% ). preferably in chlorinated organic solvents such as methylene chloride, or non- chlorinated organic solvents such as ethyl acetate, dimethyl carbonate, diethyl carbonate, acetonitrile etc.
- the formed hydrochloride of a heterocyclic compound e.g. imidazole HCl . methyl- imidazole HCl , benzimidazole HCl , tetrazole HCl etc., is filtered off or sucked ott. Organic bases may be regenerated and recycled.
- a heterocyclic compound e.g. imidazole HCl . methyl- imidazole HCl , benzimidazole HCl , tetrazole HCl etc.
- the third object of the invention is a process for the preparation of corresponding ACE inhibitors, wherein NSA (III) is reacted with corresponding derivatives ot amino acids defined below. More particularly, the object of the invention is a process for the preparation of ACE inhibitors of the formula
- R 1 and R 2 are defined as above and R has the following meanings
- inorganic salts e.g. potassium or sodium salts are used.
- organic salts preferably salts of DBU (1.8-diazabicyclo[5.4.0]undec-7-ene).
- DBN (1,5-diazabicyclo[4.3.0]non-5-ene).
- TEA triethylamine
- tetramethylguanidine imidazole. methylimidazole etc. are used.
- octahydro-1H-indole-2-carboxylic acid a pure isomer is used such as 2S,3aS,7aS or 2S,3aR,7aS, SSS or SRS trandolapril is obtained (see J. Med. Chem. 1987, 30, 992-998).
- Synthetised ACE inhibitors are recrystallized from acetonitrile or are purified by reprecipitation in ethyl acetate thus achieving high yields at purification (about 94 %).
- the mother liquor contained the novel compound N-[1-(S)-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-N- sulfoxy- anhydride or NSA, which was analyzed.
- NSA is oily liquid, unstable in humidity and air. and has a molecular weight 325 determined by iodometric titration on the basis of the following Scheme:
- NSA thus prepared may be used as starting material for the synthesis of ACE inhibitors.
- Trimethylchlorosilane (5.7 ml: 0.045 mole) was added to a mixture of L-proline (2.47 g; 0.0215 mole), anhydrous methylene chloride (90 ml) and triethylamine (2.5 ml: 0.018 mole) and the mixture was stirred for 2 hours.
- Thionylchloride (0.73 ml; 0.01 mole) was added to dry methylene chloride mixture (25 ml: H 2 O ⁇ ⁇ 0.04 % ) and the mixture was cooled to AC. Then imidazole (2.72 g: 0.04 mole) was added. The mixture was stirred for 65 minutes at a temperature between -5°C and room temperature 20°C.
- opalescent solution A (the preparation thereof is disclosed below) of siiylated (2S.3aS.7aS)- octahydro- 1 H-indole-2-carboxylic acid was added to the filtrate and an opalescent yellow solution was obtained. This solution was stirred for 1 to 6 hours at room temperature (21°C). Then the solution of H 2 O (10 ml) and NaCl (3 g) was added and 35% HCl was added to achieve pH 0.8. It was decanted and the organic phase was washed with water (5 ml). A solution of H 2 O (10 ml) and NaCl (3 g) was added to the organic phase and 33% NaOH was added to achieve pH 4.33.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU52944/96A AU5294496A (en) | 1995-04-24 | 1996-04-22 | N-sulfoxy anhydrides, a process for the preparation thereof and its use for the preparation of bioactive substances havi ng ace inhibitory action |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI9500140A SI9500140A (en) | 1995-04-24 | 1995-04-24 | Novel n-sulfoxy anhydrides, process for the preparation thereof and its use for the preparation of bioactive substances having ace inhibitory action |
SIP-9500140 | 1995-04-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996033984A1 true WO1996033984A1 (en) | 1996-10-31 |
Family
ID=20431608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SI1996/000009 WO1996033984A1 (en) | 1995-04-24 | 1996-04-22 | N-sulfoxy anhydrides, a process for the preparation thereof and its use for the preparation of bioactive substances having ace inhibitory action |
Country Status (4)
Country | Link |
---|---|
AU (1) | AU5294496A (en) |
CA (1) | CA2203435A1 (en) |
SI (1) | SI9500140A (en) |
WO (1) | WO1996033984A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1367061A1 (en) * | 2003-06-30 | 2003-12-03 | Les Laboratoires Servier | Method for synthesis of perindopril and its pharmaceutically acceptable salts |
WO2004076417A1 (en) * | 2003-02-27 | 2004-09-10 | Hetero Drugs Limited | Novel crystalline forms of trandolapril |
US7291745B2 (en) | 2005-03-21 | 2007-11-06 | Glenmark Pharmaceuticals Limited | Process for the preparation of perindopril |
US7521566B2 (en) | 2003-02-28 | 2009-04-21 | Les Laboratoires Servier | Process for preparation of perindopril and salts thereof |
US7973173B2 (en) | 2005-07-05 | 2011-07-05 | Cipla Limited | Process for the synthesis of an ACE inhibitor |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI21703A (en) | 2004-01-14 | 2005-08-31 | Lek Farmacevtska Druzba Dd | Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia |
SI21881A (en) | 2004-10-15 | 2006-04-30 | Diagen, Smartno Pri Ljubljani, D.O.O. | New crystal forms of perindopril erbumine hydrates, procedure of their preparation and pharmaceutical forms containing these compounds |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0058567A1 (en) * | 1981-02-17 | 1982-08-25 | Warner-Lambert Company | Substituted acyl derivatives of octahydro-1H-isoindole-1-carboxylic acids and esters |
EP0088341A1 (en) * | 1980-10-06 | 1983-09-14 | Warner-Lambert Company | Substituted acyl derivative of octahydro-1H-indole-2-carboxylic acid |
EP0215335A2 (en) * | 1985-08-27 | 1987-03-25 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Process for preparing N-/1(S)-ethoxycarbonyl-3-phenylpropyl/-L-alanyl-L-proline |
-
1995
- 1995-04-24 SI SI9500140A patent/SI9500140A/en not_active IP Right Cessation
-
1996
- 1996-04-22 AU AU52944/96A patent/AU5294496A/en not_active Abandoned
- 1996-04-22 WO PCT/SI1996/000009 patent/WO1996033984A1/en active Application Filing
- 1996-04-22 CA CA002203435A patent/CA2203435A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0088341A1 (en) * | 1980-10-06 | 1983-09-14 | Warner-Lambert Company | Substituted acyl derivative of octahydro-1H-indole-2-carboxylic acid |
EP0058567A1 (en) * | 1981-02-17 | 1982-08-25 | Warner-Lambert Company | Substituted acyl derivatives of octahydro-1H-isoindole-1-carboxylic acids and esters |
EP0215335A2 (en) * | 1985-08-27 | 1987-03-25 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Process for preparing N-/1(S)-ethoxycarbonyl-3-phenylpropyl/-L-alanyl-L-proline |
Non-Patent Citations (2)
Title |
---|
CHEMICAL ABSTRACTS, vol. 114, no. 9, 4 March 1991, Columbus, Ohio, US; abstract no. 81985x, LAVAYSSIERE ET AL: "Oxazoliones and dioxolones containing germanium (IV), germanium (II), phosphorus (III), sulfur." page 755; column 1; XP002008602 * |
PHOSPHORUS, SULFUR SILICON RELAT. ELEM., vol. 53, no. 1-4, 1990, pages 411 - 422 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004076417A1 (en) * | 2003-02-27 | 2004-09-10 | Hetero Drugs Limited | Novel crystalline forms of trandolapril |
US7521566B2 (en) | 2003-02-28 | 2009-04-21 | Les Laboratoires Servier | Process for preparation of perindopril and salts thereof |
EP1367061A1 (en) * | 2003-06-30 | 2003-12-03 | Les Laboratoires Servier | Method for synthesis of perindopril and its pharmaceutically acceptable salts |
WO2005003153A1 (en) * | 2003-06-30 | 2005-01-13 | Les Laboratoires Servier | Novel method of synthesising perindopril and the pharmaceutically-acceptable salts thereof |
US7179833B2 (en) | 2003-06-30 | 2007-02-20 | Les Laboratoires Servier | Method of synthesising perindopril and the pharmaceutically acceptable salts thereof |
EA008836B1 (en) * | 2003-06-30 | 2007-08-31 | Ле Лаборатуар Сервье | Novel method of synthesising perindopril and the pharmaceutically-acceptable salts thereof |
AU2004253721B2 (en) * | 2003-06-30 | 2007-12-20 | Les Laboratoires Servier | Novel method of synthesising perindopril and the pharmaceutically-acceptable salts thereof |
US7291745B2 (en) | 2005-03-21 | 2007-11-06 | Glenmark Pharmaceuticals Limited | Process for the preparation of perindopril |
US7973173B2 (en) | 2005-07-05 | 2011-07-05 | Cipla Limited | Process for the synthesis of an ACE inhibitor |
Also Published As
Publication number | Publication date |
---|---|
AU5294496A (en) | 1996-11-18 |
CA2203435A1 (en) | 1996-10-31 |
SI9500140A (en) | 1996-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR890002104B1 (en) | Method for preparing 4-substituted-2-azetidinone compound | |
CA1205476A (en) | Substituted acyl derivatives of octahydro-1h-indole-2- carboxylic acids | |
FR2663336A1 (en) | NOVEL PEPTIDE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
HUT68200A (en) | Process for producing peptides inhibiting il-1-beta release and pharmaceutical compositions containing them as active component | |
ES2371699T3 (en) | NEW DIAZENIO DIOLATE DERIVATIVES, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
US5359086A (en) | Process for preparing alkyl-L-alanyl-L-proline derivatives | |
WO1996033984A1 (en) | N-sulfoxy anhydrides, a process for the preparation thereof and its use for the preparation of bioactive substances having ace inhibitory action | |
US4537714A (en) | Process for the preparation of lower alkyl esters of N-L-α-aspartyl-L-phenylalanine and of new intermediates for their preparation | |
EP0285992B1 (en) | Crystalline quinapril and a process for producing the same | |
EP1371659B1 (en) | Method for synthesis of perindopril and its pharmaceutically acceptable salts [2003/26] | |
JPS6332073B2 (en) | ||
US4761495A (en) | Method relating to preparation of aspartyl peptides | |
SU1375123A3 (en) | Method of producing n-substituted l-amino acids | |
SI21704A (en) | New crystal form of perindopril, procedure of its preparation, pharmaceutical preparations containing this form and their application in treatment of hypertensia | |
US5789597A (en) | Process for the preparation of compounds having ACE inhibitory action and intermediates in said process | |
EP0839128B1 (en) | Process for the preparation of ethyl 3s-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-pentynoate | |
HU188177B (en) | Process for producing new proline derivatives | |
EP0015773A2 (en) | N-(6-((acylaminoacylamino or aminoacylamino)phenyl) 1,2-dihydro-2-oxonicotinyl)penicillin compounds, processes for their production and compositions containing them | |
WO2001040263A1 (en) | 1,3,4-oxadiazolin-2-one derivatives and drugs containing these derivatives as the active ingredient | |
HU222843B1 (en) | Nalpha-2-(4-nitrophenylsulfonyl)ethoxycarbonyl-amino acids and process for production them | |
US5126451A (en) | Renin inhibitors containing α-heteroatom amino acids | |
KR100273765B1 (en) | Method for preparing N- (4-piperidine) benzamide and new active thioester as an intermediate thereof and method for preparing same | |
US6063962A (en) | Process for the preparation of NMDA antagonists | |
US5962722A (en) | α-hydrazino acid derivatives and method for making same | |
HU185953B (en) | Process for producing new 4.cabamoyloxy-oxaza-phosphorines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1997 817298 Date of ref document: 19970415 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref document number: 2203435 Country of ref document: CA Ref country code: CA Ref document number: 2203435 Kind code of ref document: A Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |